These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 19778313)
21. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Tan SK; Tay YK Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108 [TBL] [Abstract][Full Text] [Related]
22. Stevens-Johnson syndrome and toxic epidermal necrolysis: consequence of treatment of an emerging pathogen. Mistry RD; Schwab SH; Treat JR Pediatr Emerg Care; 2009 Aug; 25(8):519-22. PubMed ID: 19687711 [TBL] [Abstract][Full Text] [Related]
24. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523 [TBL] [Abstract][Full Text] [Related]
25. [Analysis of treatments and deceased cases of severe adverse drug reactions--analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis]. Yamane Y; Aihara M; Tatewaki S; Matsukura S; Kanbara T; Yamakawa Y; Ikezawa Z Arerugi; 2009 May; 58(5):537-47. PubMed ID: 19487835 [TBL] [Abstract][Full Text] [Related]
31. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Yeung CK; Lam LK; Chan HH Clin Exp Dermatol; 2005 Sep; 30(5):600-2. PubMed ID: 16045716 [No Abstract] [Full Text] [Related]
32. Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome. Chattopadhyay P; Sarma N Singapore Med J; 2011 Feb; 52(2):e31-4. PubMed ID: 21373727 [TBL] [Abstract][Full Text] [Related]
33. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients. Saito N; Yoshioka N; Abe R; Qiao H; Fujita Y; Hoshina D; Suto A; Kase S; Kitaichi N; Ozaki M; Shimizu H J Allergy Clin Immunol; 2013 Feb; 131(2):434-41.e1-9. PubMed ID: 23111236 [TBL] [Abstract][Full Text] [Related]
34. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Porteous DM; Berger TG Arch Dermatol; 1991 May; 127(5):740-1. PubMed ID: 1827245 [No Abstract] [Full Text] [Related]
35. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. Abe R J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400 [TBL] [Abstract][Full Text] [Related]
36. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164 [TBL] [Abstract][Full Text] [Related]
37. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091 [TBL] [Abstract][Full Text] [Related]
38. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Gueudry J; Roujeau JC; Binaghi M; Soubrane G; Muraine M Arch Dermatol; 2009 Feb; 145(2):157-62. PubMed ID: 19221260 [TBL] [Abstract][Full Text] [Related]
39. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Khalili B; Bahna SL Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130 [TBL] [Abstract][Full Text] [Related]